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CASE REPORT
Dramatic response to alectinib  
in a patient of ALK-rearranged lung cancer 
with poor performance status
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Shingo Takanashi3 and Ken Okumura1
Abstract 
Background: Lung cancers with anaplastic lymphoma kinase rearrangements are highly sensitive to anaplastic 
lymphoma kinase tyrosine kinase inhibition, underscoring the notion that such cancers are addicted to anaplastic 
lymphoma kinase activity. Several anaplastic lymphoma kinase inhibitors have been identified and are being evalu-
ated in clinical trials. However patients with poor performance status (3 or 4) were not involved in these clinical trials, 
it has been unclear to use anaplastic lymphoma kinase–tyrosine kinase inhibitors for these patients. Here, we report 
an anaplastic lymphoma kinase-positive non small cell lung cancer patient with performance status 4, who was suc-
cessfully treated with alectinib.
Case presentation: We report on a 52-year-old patient diagnosed as non small cell lung cancer harboring echino-
derm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. His performance status was 4 
because of severe respiratory failure. We treated this patient with alectinib as the first line therapy. Dramatic response 
was obtained and his performance status improved from 4 to 1 without severe adverse events.
Conclusion: Alectinib is a therapeutic option for the anaplastic lymphoma kinase positive patients with poor perfor-
mance status.
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Background
Non small cell lung cancer (NSCLC) is the leading cause 
of cancer-related deaths worldwide. Platinum-based 
chemotherapy is the standard therapy for patients with 
metastatic or recurrent disease. However, platinum-
based chemotherapy is not recommended for patients 
with poor performance status (PS) of 3 or 4. Recently 
oncogenic drivers have been identified to play essen-
tial roles in the tumorigenesis, survival and prolifera-
tion in lung cancer. The National Comprehensive Cancer 
Network recommends epidermal growth factor recep-
tor (EGFR) tyrosine kinase inhibitor (TKI) as a salvage 
treatment option for NSCLC patients with poor PS. 
While there has been a study looking at crizotinib ver-
sus chemotherapy in anaplastic lymphoma kinase (ALK) 
positive NSCLC [1], there is no prospective clinical evi-
dence that indicates the efficacy of ALK TKIs for ALK 
positive patients with poor PS.
Case report
A 52-year-old man who was a smoker presented with 
severe respiratory failure. There was no special family 
history. A chest computed tomography (CT) showed a 
tumor in the right lower lung with atelectasis and mul-
tiple lung metastases in bilateral lung fields (Fig.  1a). 
Bone scintigraphy showed a hot spot on his lumber ver-
tebrate, and thus clinical stage was IV (cT4N3M1b). As 
for his breathing state, SpO2 was around 90 % under the 
conditions of an oxygen flow rate 10 L/min with reservoir 
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bag mask. His performance status (PS) was 4. Best sup-
portive care seemed to be a proper choice. His medical 
history was unremarkable, and he had taken no medica-
tions. He had smoked 34 pack-years. The serum carci-
noembryonic antigen (CEA) level was 8.6 ng/mL (normal 
range, 0–5.0  ng/mL). We conducted bronchoscopy by 
using high-flow nasal cannulae to make a pathological 
diagnosis and to assess molecular status. The diagnosis 
was adenocarcinoma, and moreover molecular analysis 
revealed that ALK protein was positive by immunohisto-
chemical staining and ALK rearrangement was positive 
by reverse transcription polymerase chain reaction (RT-
PCR). Fluorescence in situ hybridization (FISH) test was 
indeterminate.
Therefore, we treated the patient with alectinib at 
300  mg twice daily. In 3  weeks, chest CT showed dra-
matic shrinkage of the primary tumor in the right lower 
lobe and bilateral multiple lung metastases (Fig.  1b). 
Bronchoscopic study also showed dramatic improve-
ment in right lower bronchus (Fig.  2a, b). The only 
adverse event was grade 1 elevation of alanine ami-
notransferase (ALT). The ALT level was 19 U/L before 
treatment, the maximum ALT level was 59 U/L during 
treatment. This adverse event was manageable. His PS 
improved from 4 to 1, the Karnofsy Performance Scale 
(KPS) improved from 10 to 90 %, and he discharged in 
4 weeks his PS improved from 4 to 1 and he discharged 
in 4 weeks.
Discussion
The echinoderm microtubule-associated protein-like 4 
(EML4)-ALK, a fusion gene first described in 2007, pos-
sesses oncogenic activity that can be blocked by ALK 
inhibitor [2], and Rikova et  al. [3] described two ALK 
fusion partners. Alectinib is a novel, highly selective oral 
ALK inhibitor [4, 5]. Seto et al. reported the efficacy and 
safety of alectinib in ALK inhibitor-naive patients with 
ALK-rearranged lung cancer in a phase 1–2 study. The 
overall response rate in the phase 2 part of the study was 
93.5 %. The mean duration of treatment was 14.8 months, 
and at 1 year of follow-up, the median PFS had not been 
reached. The adverse events of alectinib were less than 
crizotinib [6]. There were no treatment-related grade 4 
adverse events or deaths. Therefore, we chose alectinib 
for our patient. At present, crizotinib and alectinib are 
available as ALK inhibitors in Japan. The phase 3 stud-
ies (JapicCTI-132316, NCT02075840) comparing alec-
tinib with crizotinib in the patients with chemo-naive, 
advanced ALK-rearranged lung cancer are ongoing. The 
superiority between the two drugs is not clear until the 
results of these trials come out. It should be pointed out 
that these clinical trials do not involve the patients with 
poor PS such as PS 3 or 4. In crizotinib, there are a few 
reports indicate the efficacy of crizotinib therapy for the 
patients with poor PS. Tamai et al. [7] reported a patient 
with ALK positive lung adenocarcinoma who was admin-
istered crizotinib via nasogastric and percutaneous endo-
scopic gastrostomy tubes. Ahn et al. [8] reported in the 
case of EGFR-mutated patients with poor PS, gefitinib 
is recommended as a first-line treatment. Inoue et al. [9] 
reported that the efficacy and feasibility of gefitinib for 
patients with poor PS and EGFR mutations. The objec-
tive tumor response rate was 66  % and toxicities were 
comparable to that observed in patients with PS 0–2. In 
the patients of an oncogene addicted lung cancer with 
Fig. 1 Computed tomography scan of the chest before the initiation 
of alectinib showing atelectasis in the right lower lung and multi-
ple lung metastases (a). Computed tomography scan of the chest 
3 weeks after the initiation of alectinib showing improvement of 
the atelectasis in the right lower lung and reduction of multiple lung 
metastases (b)
Fig. 2 Bronchoscopy showing tumor obstruction in a visible range 
from the truncus intermedius to right lower lobe bronchus (a). 
Bronchoscopy taken 2 weeks after the initiation of alectinib showing 
dramatic shrinkage of right lower bronchus (b)
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poor PS, cytotoxic chemotherapy is not applicable, how-
ever, molecular target therapy might be feasible. Now, we 
can use two ALK-TKIs (crizotinib and alectinib) in Japan 
however, these ALK-TKIs have not been recommended 
in Japanese guideline because of no clinical evidence for 
such poor PS. To the best of our knowledge, this is the 
first case report of dramatic response to alectinib in an 
ALK-rearranged lung adenocarcinoma patient with PS 4.
Conclusions
This case suggests alectinib could be a therapeutic option 
for such patients. Obviously, further study is necessary 
(UMIN000015094).
Consent
Written informed consent was obtained from the patient 
for publication of this case report and accompanying 
images.
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